iRhythm Holdings (NASDAQ: IRTC) reported an insider sale by Chief Accounting Officer Marc Wade Rosenbaum, who sold 280 shares of common stock on February 24, 2026, at $140.91 per share. The transaction was recorded on a Form 4 filed with the Securities and Exchange Commission and amounted to approximately $39,454.
Following the disposition, Rosenbaum directly holds 10,601 shares of iRhythm. The filing states the trade was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that was originally established on May 12, 2025, and later modified on November 25, 2025.
At the time the insider sale was reported, iRhythm's stock was trading at $135.85, reflecting a 14% decline over the previous week and a 23% decline year-to-date. The price movement provides the market context for the transaction but the sale itself was executed under the previously disclosed 10b5-1 program.
Separately, iRhythm Technologies announced fourth-quarter financial results that showed revenue of $208.9 million, a 27.1% increase from the prior year and above the company’s earlier preannouncement of more than $201.8 million. Management attributed the outperformance to strong contribution from ZioAT and progress with channel partners.
The company also reported positive GAAP net income for the first time and produced an adjusted EBITDA of $34.3 million. These results coincided with guidance for 2026 revenue in the range of $870 million to $880 million, representing growth of roughly 17% to 18% year-over-year. iRhythm projects an adjusted EBITDA margin of approximately 11.5% to 12.5% for 2026, a set of targets management said are supported by record unit volume in the fourth quarter.
Following the results, several research firms updated their views. Truist Securities and Canaccord Genuity both lowered their price targets to $200 and $198 respectively, while each maintained a Buy rating. Morgan Stanley reiterated an Overweight rating with a $205 price target.
The insider sale, the quarterly performance, analyst target adjustments, and the company’s forward-looking guidance together provide a mixed signal: company fundamentals showing clear operational improvement, while near-term stock performance and analyst target moves reflect ongoing market re-pricing.